Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Pfizer is presented as the preferred 2026 investment on a lower 9.5x forward P/E and 2.5x P/S ratio versus Novo Nordisk's 11.2x and 3.4x, respectively. Pfizer generated $62.6B of FY2025 revenue, down 1.6%, and $7.8B of net income, but is expected to lift net income to $8.9B this year through oncology growth, pipeline investment and obesity expansion following Seagen and Metsera acquisitions. Novo posted $46.5B in FY2025 revenue and a 33% net margin, but consensus expects FY2026 sales to decline about 3% and net income to fall 4% amid GLP-1 pricing pressure and stronger competition.

Analysis

The actionable read is not PFE versus NVO on headline multiples; it is execution-adjusted earnings durability. PFE's discount will persist unless Seagen-derived growth and the obesity pipeline offset the patent-loss and IRA price-reset curve on a product-by-product basis. NVO's apparent de-rating is more consequential: a modest revenue decline can produce disproportionate EPS pressure because GLP-1 price concessions, mix shift toward oral therapies, and manufacturing underutilization all challenge the margin premium embedded in its historical model.

LLY is the cleaner competitive beneficiary of any NVO pricing or supply slippage. Its advantage is not simply share gains: a broader obesity market permits LLY to prioritize higher-value indications and payer contracts, while NVO may have to defend volume at lower net prices. Conversely, PFE's obesity optionality should not yet be capitalized as a commercial franchise; Phase II results have limited valuation relevance until Phase III efficacy, tolerability, discontinuation rates, and scalable manufacturing are independently established.

Over the next 1-3 months, NVO guidance revisions and U.S. prescription/net-price data matter more than patent duration, while PFE's near-term rerating requires pipeline-readout quality rather than another revenue beat. Over 6-18 months, Medicare negotiation implementation and competitive GLP-1 formulary positioning could reset the sector's terminal-margin assumptions. The contrarian risk is that consensus treats PFE as a cheap defensive compounder: oncology integration, litigation, and concentration make its earnings stream less bond-like than its multiple implies.

Key Decisions for Investors

• Maintain or initiate a 6-12 month long LLY / short NVO pair, sized beta-neutral. The trade captures relative GLP-1 pricing power and product-cycle momentum; reassess if NVO demonstrates sustained prescription-share stabilization and maintains gross-margin guidance through the next two reporting cycles.
• Do not underwrite a directional PFE long solely on its forward P/E. Use a watch trigger: consider initiating only after management quantifies Seagen synergies, raises multi-year revenue-offset guidance, or Phase III obesity data establish competitive efficacy/tolerability; downside is renewed patent-cliff guidance pressure and litigation reserve escalation.
• For existing NVO exposure, reduce into strength or hedge over the next two earnings dates with put spreads rather than assuming the 2032 injectable patent protects economics. Thesis is falsified by improving U.S. net-price realization, stable capacity utilization, and an upward revision to FY earnings expectations.
• Use MRNA only as a vaccine-volatility hedge or tactical readout vehicle, not as a direct beneficiary of PFE's transition. Vaccine competition is too small relative to PFE's oncology, IRA, and obesity execution variables to support a clean relative-value trade.